Therapeutic Apheresis, Immunosuppression, and Human Monoclonal Antibodies in Hematologic Diseases

To cure a patient by removing his illness extracting blood is very old one. Now this process, bloodletting, placed on rational basis with therapeutic apheresis using hollow fiber membranes, being our clinical practice. Based many years of experience extracorporeal circulation in end-stage renal disease, the authors herein give an overview TA hematologic diseases, immunologic or non-immunologic origin. Immunology and molecular biology different diseases are discussed relation to rationale for therapies, its place alone combination other modern such as immunosuppression, HMAs, tyrosine kinase inhibitors, recombinant factor VVII, VIII, others. The prognosis most has improved recent years, due part aggressive therapy methods. Therapeutic indicated only severe diseases. guidelines Apheresis Application Committee American Society which could be treated methods cited. been shown effectively remove autoantibodies, toxins, pathologic substances from lead rapid improvement, it can safely performed even all ill patients, and/or human monoclonal antibodies.